Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Outlook Therapeutics (OTLK) over the last 8 years, with Q4 2025 value amounting to $18.2 million.

  • Outlook Therapeutics' Liabilities and Shareholders Equity rose 724.75% to $18.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $78.3 million, marking a year-over-year increase of 1051.28%. This contributed to the annual value of $18.6 million for FY2025, which is N/A changed from last year.
  • As of Q4 2025, Outlook Therapeutics' Liabilities and Shareholders Equity stood at $18.2 million, which was up 724.75% from $18.6 million recorded in Q3 2025.
  • Outlook Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $22.4 million for Q2 2025, and its period low was $17.0 million during Q4 2024.